<DOC>
	<DOCNO>NCT01450982</DOCNO>
	<brief_summary>The purpose study evaluate effect JNJ-38518168 pharmacokinetics ( body handle drug ) methotrexate participant rheumatoid arthritis .</brief_summary>
	<brief_title>A Study Investigate How JNJ-38518168 May Affect Plasma Levels Methotrexate Rheumatoid Arthritis Participants</brief_title>
	<detailed_description>This open-label ( physician participant know name assign drug ) , multi-center , non-randomized , drug/drug interaction study JNJ-38518168 participant rheumatoid arthritis ( RA ) stable oral methotrexate ( MTX ) dose ( 7.5-25 mg ) . The treatment phase last 16 day . Participants house clinic dosing study procedure Day -1 Day 2 Day 14 Day 16 . Participants complete treatment follow-up visit Days 22 25 . Participants discontinue study prematurely complete Day 22 25 follow-up procedure time discontinuation soon possible thereafter . The duration participation study individual participant 7 week ( include screen ) . Participant safety monitor . Day 1 : A single oral dose participant 's weekly methotrexate dose . Days 2-15 : Weekly MTX co-administered two 50-mg capsule JNJ-38518168 , administer daily .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Have body mass index ( BMI ) 18 38 kg/m2 inclusive , body weight 50110 kg , inclusive Have diagnosis Rheumatoid Arthritis functional class IIII least 3 month prior Screening Have treat tolerate oral MTX treatment minimum 3 month prior screen must onceweekly stable MTX dose ( take single dose ) ( 7.525 mg/week ) minimum 1 month Participants may continue stable nonsteroid antiinflammatory drug corticosteroid background therapy RA stable therapy condition prescribe physician , provided dos therapy stable least 1 month prior screen remain unchanged entire study duration . Have current sign symptom liver renal insufficiency cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , hematologic , psychiatric , metabolic disturbance severe , progressive uncontrolled study doctor 's opinion Have treat monoclonal antibody RA serious infection 2 week study treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>JNJ-38518168</keyword>
	<keyword>Methotrexate</keyword>
</DOC>